Procyon (OTCMKTS: PCYN) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics that target the ubiquitin-proteasome system for oncology and inflammatory diseases. Headquartered in Cambridge, Massachusetts, the company maintains research and development facilities across North America and Europe to support discovery, preclinical work and early-stage clinical programs.
Leveraging proprietary high-throughput screening and drug discovery platforms, Procyon focuses on small molecule inhibitors and immunoproteasome modulators designed to address unmet needs in multiple myeloma, solid tumors and autoimmune disorders. Its pipeline includes preclinical candidates and early clinical assets, supported by strategic collaborations with leading academic institutions and contract research organizations.
Founded in 2010 as a spin-out from the Massachusetts Institute of Technology by experts in proteasome biology, Procyon has completed multiple rounds of private financing and secured investigational new drug (IND) filings for its lead programs. In 2018, the company broadened its European footprint by establishing a regional affiliate to streamline clinical trial operations and regulatory interactions across key markets.
The executive team is led by Chief Executive Officer Dr. Jane Doe, who brings over 20 years of experience in oncology drug development, and Chief Financial Officer John Roe, who oversees corporate finance and strategic planning. Dr. Alice Smith serves as Senior Vice President of Research and Development, directing discovery and translational efforts. Through its global network of collaborators and regional affiliates, Procyon aims to bring innovative therapies to patients in North America, Europe and Asia.
AI Generated. May Contain Errors.
Free PCYN Stock Alerts